AKBA Akebia Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AKBA

Price (delayed)

$0.8696

Market cap

$240.97M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.11

Enterprise value

$139.39M

?
Relative Growth: Rel. Growth: 18
Relative Strength: Rel. Strength: 6
Relative Valuation: Rel. Valuation: 27
Relative Profitability: Rel. Profitability: 34

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered ...

Highlights
The company's gross margin rose by 7% YoY
AKBA's net income is down by 45% from the previous quarter but it is up by 19% YoY
Akebia Therapeutics's EPS has increased by 39% YoY but it has decreased by 38% from the previous quarter
The company's quick ratio fell by 27% YoY
The equity is down by 14% year-on-year and by 9% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.akebia.com
Peers: JNJ NVS AMGN NKTR

Key stats

What are the main financial stats of AKBA

AKBA stock price

How has the Akebia Therapeutics stock price performed over time
Intraday
-2.64%
1 week
-8.89%
1 month
-36.99%
1 year
-73.65%
YTD
-45.99%
QTD
-23.72%

Financial performance

How have Akebia Therapeutics's revenue and profit performed over time
Revenue
$219.06M
Gross profit
$174.43M
Operating income
-$11.77M
Net income
-$29.67M
Gross margin
79.6%
Net margin
-13.5%
AKBA's net margin has dropped by 53% since the previous quarter but it is up by 25% year-on-year
AKBA's net income is down by 45% from the previous quarter but it is up by 19% YoY
AKBA's gross profit is up by 15% year-on-year but it is down by 7% since the previous quarter
Akebia Therapeutics's revenue has increased by 8% YoY but it has decreased by 6% QoQ

Price vs fundamentals

How does AKBA's price correlate with its fundamentals

Growth

What is Akebia Therapeutics's growth rate over time

Valuation

What is Akebia Therapeutics stock price valuation
P/E
N/A
P/B
9.32
P/S
1.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.64
Akebia Therapeutics's EPS has increased by 39% YoY but it has decreased by 38% from the previous quarter
AKBA's P/B is 34% below its last 4 quarters average of 14.1
The equity is down by 14% year-on-year and by 9% since the previous quarter
The price to sales (P/S) is 47% less than the last 4 quarters average of 2.0 and 33% less than the 5-year quarterly average of 1.6
Akebia Therapeutics's revenue has increased by 8% YoY but it has decreased by 6% QoQ

Efficiency

How efficient is Akebia Therapeutics business performance
Akebia Therapeutics's return on equity has decreased by 49% QoQ
The ROA has contracted by 44% from the previous quarter but it has grown by 39% YoY
Akebia Therapeutics's ROS has decreased by 17% YoY

Dividends

What is AKBA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKBA.

Financial health

How did Akebia Therapeutics financials performed over time
AKBA's total assets is 8% greater than its total liabilities
Akebia Therapeutics's current ratio has decreased by 28% YoY but it has increased by 2.1% QoQ
The company's quick ratio fell by 27% YoY
AKBA's debt is 116% greater than its equity
The debt to equity has increased by 33% year-on-year and by 21% since the previous quarter
The equity is down by 14% year-on-year and by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.